Immunodeficiency Therapeutics MarketSize and Trends

The global immunodeficiency therapeutics market is estimated to be valued at US$ 6,991.1 Mn in 2021, and is expected to exhibit a CAGR of 6.1% over the forecast period (2021-2028).

The rising cases of immunodeficiency diseases is the major factor that is expected to drive the global immunodeficiency therapeutics market growth over the forecast period.

The rising prevalence of immunodeficiency disease is expected to drive growth of global immunodeficiency therapeutics market over the forecast period. For instance, according to an article published by the National Institutes for Health (NIH), U.S. in May 2021, the prevalence of ADA-SCID (Adenosine deaminase-severe combined immunodeficiency syndrome) is estimated to be one in 200,000 to 1,000,000 newborns across the world. Moreover, according to the data published by the World Health Organization (WHO) in November 2020, around 1.5 million new human immunodeficiency virus (HIV) infections were reported globally in 2020 and 37.6 million are reported to be suffering from HIV worldwide in 2020. HIV causes acquired immunodeficiency disorder syndrome (AIDS).

Figure 1: Global Immunodeficiency Therapeutics Market Share (% ) Analysis, By Therapy Type, 2021

Moreover, increasing number of research and development activities for improving the effectiveness of immunodeficiency therapeutics is expected to aid in the growth of the market over the forecast period. For instance, according to an article published by National Institute of Health (NIH) in May 2021, an investigational research study conducted in in U.S. and U.K. and supported by NIH showed that., 96% of children receiving new experimental lentiviral gene therapy for immunodeficiency diseases reported restored immune function.

The rising advancements of technology in the field of genetics is expected to drive the growth of the global immunodeficiency therapeutics market over the forecast period. For instance, according to an article published in the Genes & Diseases international scientific journal in March 2020, recent technological advancements such as next generation sequencing (NGS) have enabled researchers to explore newer genetic variations related to common variable immunodeficiency (CVID) in order to improve its diagnosis.